MTOR and hepatocellular carcinoma: To comprehensively validate the interplay between Let‐7b‐5p and the IGF1R/AKT/mTOR signaling pathway in the context of HCC progression, a well‐designed experimental approach was adopted, which included the use of a Let‐7b‐5p inhibitor.